title: Treatment of chronic HBV infection in developing countries.
abstract: Due to virological, host and socio-economic factors, the clinical presentation and treatment of chronic hepatitis B (CHB) differs between developing and developed countries and may differ between one low-income country and another. National healthcare prevention and treatment policies, environmental factors, social habits and personal life-styles all influence HBV transmission and the clinical management and therapy of CHB. These factors can have a strong impact on the natural history of the disease and on Access to treatment and may eventually determine substantial changes in disease progression and the development of serious complications and hepatocellular carcinoma. In this review article, we analyze the clinical characteristics and access to antiviral treatment of CHB patients in low-income countries in Africa, Asia, Eastern Europe and Latin America.
authors.affiliation: Internal Medicine and Hepatology, ** Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara".
authors.forename: Rosa
authors.initials: R
authors.lastname: Zampino
authors.affiliation: Department of Mental Health and Public Medicine, Honorary Professor of Infectious Diseases.
authors.forename: Caterina
authors.initials: C
authors.lastname: Sagnelli
authors.affiliation: Internal Medicine and Hepatology, ** Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara".
authors.forename: Adriana
authors.initials: A
authors.lastname: Boemio
authors.affiliation: Department of Mental Health and Public Medicine, Honorary Professor of Infectious Diseases.
authors.forename: Evangelista
authors.initials: E
authors.lastname: Sagnelli
authors.affiliation: Department of Mental Health and Public Medicine, Section of Infectious Diseases. Second University of Naples, Naples, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Coppola
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019033:Delivery of Health Care, Integrated / Q000458:organization & administration; D003906:Developing Countries; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D006515:Hepatitis B virus / Q000187:drug effects* / Q000472:pathogenicity; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents